
BioMarin CEO expects 'substantial' profitability after FDA approval of hemophilia drug
Jim Cramer chats with Jean-Jacques Bienaimé, chairman and CEO of BioMarin, which focuses on therapies to treat rare diseases.
UP NEXT
UP NEXT
-
IIF discusses the rise in corporate debt and global leverage
CNBC
-
JP Morgan: We're still positive on Chinese stocks
CNBC
-
Economist: I'm still worried about the repo market in the US
CNBC
-
There will be some headwinds for Saudi Aramco: Strategist
CNBC
-
Reputational damage for Westpac could get 'worse': Strategist
CNBC
-
'Slow and steady' process for Boeing to regain trust: Analyst
CNBC
-
The UK won't end up with a hung parliament: TD Ameritrade Singapore
CNBC
-
Why Indian markets are 'moving ahead of fundamentals'
CNBC
-
'Very limited room' for monetary policy in China: Economist
CNBC
-
We're 'pretty positive' on Chinese markets, says SEB
CNBC
-
A rerating in the pound could occur 'quite rapidly': NatWest
CNBC
-
China is slowing down 'permanently,' says economist
CNBC
-
Saudi Aramco is an 'unusual' company: JTD Energy Services
CNBC
-
Discussing the outlook for new Asian ADRs in 2020
CNBC
-
Expecting Saudi Aramco to hit $2 trillion valuation: Energy expert
CNBC
-
UK election is of generational importance: Expert
CNBC